CARLSBAD, Calif., June 18 CA-AutoGenomicsPatent
CARLSBAD, Calif., June 18 /PRNewswire/ -- AutoGenomics, a leader in
providing automated, molecular testing solutions, announced today that it has
been issued a key European patent for Human papillomavirus. Patent No.1 499
749 B1, "Human papillomavirus Detection with DNA Microarray," claims to be a
method for detecting the presence of HPV using a microarray.
"This patent is the result of our collaboration with Dr. Erik Thunnissen,
a prominent clinician and opinion leader in the field of Human
papillomavirus," said Mr. Fareed Kureshy, President and CEO of AutoGenomics.
He further said that "with increasing demands for alternative technologies to
meet the evolving need for genotyping we are excited that we can offer an
automated solution that can significantly enhance workflow efficiency in the
laboratory".
About AutoGenomics
AutoGenomics Inc., a privately held company based in Carlsbad, CA., has
developed the first automated, microarray based multiplexing diagnostic
platform that can be used to assess disease signatures with novel genomic and
proteomic markers in the area of genetic disorders, infectious disease, cancer
and pharmacogenetics. With the discovery of genes and their link to various
disease states the platform has the versatility to revolutionize the way
patients are diagnosed, monitored and managed, leading to the era of
personalized medicine. www.autogenomics.com
SOURCE AutoGenomics Inc.
